HC Wainwright Issues Pessimistic Forecast for Myomo (NYSEAMERICAN:MYO) Stock Price

Key Points

• HC Wainwright has cut Myomo's price target from $9.50 to $5.00, while maintaining a "buy" rating, suggesting a significant potential upside of 184.09% from the current stock price.
• Despite the price target reduction, other analysts, such as Craig Hallum and Ascendiant Capital Markets, continue to rate the stock as a "buy" with targets of $8.00 and $11.50, respectively.
• Recent insider activity includes purchases by Director Thomas F. Kirk and CEO Paul R. Gudonis, indicating increased confidence from company leadership in Myomo's future.

Myomo (NYSEAMERICAN:MYO - Free Report) had its price objective lowered by HC Wainwright from $9.50 to $5.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Myomo's Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.35 EPS.

A number of other equities research analysts have also issued reports on the company. Craig Hallum set a $8.00 price target on Myomo and gave the stock a "buy" rating in a research note on Monday, June 23rd. Ascendiant Capital Markets increased their price objective on Myomo from $11.00 to $11.50 and gave the company a "buy" rating in a research note on Thursday, June 5th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Myomo in a research report on Thursday, June 26th.

Myomo Stock Down 0.5%

Shares of NYSEAMERICAN MYO traded down $0.01 during trading hours on Tuesday, reaching $0.98. 3,247,241 shares of the stock traded hands, compared to its average volume of 1,114,762. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 2.37. The business's 50-day moving average is $2.12. The stock has a market cap of $36.86 million, a P/E ratio of -4.24 and a beta of 1.40. Myomo has a 52-week low of $0.92 and a 52-week high of $7.17.

Hedge Funds Weigh In On Myomo

A number of hedge funds have recently bought and sold shares of the company. Vontobel Holding Ltd. boosted its stake in shares of Myomo by 20.2% in the 1st quarter. Vontobel Holding Ltd. now owns 27,219 shares of the company's stock valued at $131,000 after purchasing an additional 4,574 shares in the last quarter. Summit Financial Strategies Inc. boosted its holdings in shares of Myomo by 50.0% during the 2nd quarter. Summit Financial Strategies Inc. now owns 15,000 shares of the company's stock valued at $32,000 after acquiring an additional 5,000 shares during the last quarter. Northern Trust Corp lifted its holdings in Myomo by 17.6% during the fourth quarter. Northern Trust Corp now owns 49,587 shares of the company's stock valued at $319,000 after purchasing an additional 7,413 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Myomo during the fourth quarter valued at approximately $64,000. Finally, Walleye Capital LLC bought a new stake in Myomo in the fourth quarter worth $66,000. Institutional investors own 44.99% of the company's stock.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.